Evidence map›Paper›PMID 37681545›Full record

ArticleJournal of the American Heart Association2023

Arginine Vasopressin Plays a Role in Microvascular Dysfunction After ST-Elevation Myocardial Infarction.

Ayman Al-Atta, Luke Spray, Ashfaq Mohammed, Evgeniya Shmeleva, Ioakim Spyridopoulos

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Ayman Al-AttaFreeman Hospital Newcastle upon Tyne United Kingdom.ORCID 0000-0003-2335-9596
Luke SprayFreeman Hospital Newcastle upon Tyne United Kingdom.ORCID 0000-0001-8295-0373
Ashfaq MohammedFreeman Hospital Newcastle upon Tyne United Kingdom.
Evgeniya ShmelevaTufts University Boston MA USA.ORCID 0000-0002-7654-2960
Ioakim SpyridopoulosFreeman Hospital Newcastle upon Tyne United Kingdom.ORCID 0000-0002-2750-2444
Freeman Hospital · GBTufts University · US

Funding

British Heart Foundation PG/22/10788British Heart Foundation PG/23/11093
6 · The paper itself

Abstract

Background Coronary microvascular dysfunction (CMD) predicts mortality after ST-elevation-myocardial infarction (STEMI). Arginine vasopressin (AVP) may be implicated, but data in humans are lacking, and no study has investigated the link between arginine vasopressin and invasive measures of CMD. Methods and Results We invasively assessed CMD in 55 patients with STEMI treated with primary percutaneous coronary intervention (PPCI), by measuring the index of microcirculatory resistance after PPCI. In a separate group of 45 patients with STEMI/PPCI, recruited for a clinical trial, we measured infarct size and microvascular obstruction with cardiac magnetic resonance (CMR) imaging at 1 week and 12 weeks post-STEMI. Serum copeptin was measured at 4 time points before and after PPCI in all patients with STEMI. Plasma copeptin levels fell from 92.5 pmol/L before reperfusion to 6.4 pmol/L at 24 hours. Copeptin inversely correlated with diastolic, but not systolic, blood pressure (r=-0.431,

Indexed as

Coronary Artery DiseaseMyocardial IschemiaST Elevation Myocardial InfarctionArginine VasopressinHumansMicrocirculationArginine Vasopressinacute myocardial infarctioncopeptinmicrovascular dysfunctionmicrovascular obstruction

Identifiers

PMID37681545
PMCPMC10547306
OpenAlexW4386530889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.